- Home
- LTC vs VRDN Comparison
LTC vs VRDN Comparison
Compare LTC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTC
- VRDN
- Stock Information
- Founded
- LTC 1992
- VRDN 2006
- Country
- LTC United States
- VRDN United States
- Employees
- LTC 23
- VRDN N/A
- Industry
- LTC Real Estate Investment Trusts
- VRDN Medical Specialities
- Sector
- LTC Real Estate
- VRDN Health Care
- Exchange
- LTC Nasdaq
- VRDN Nasdaq
- Market Cap
- LTC 1.7B
- VRDN 1.5B
- IPO Year
- LTC 1992
- VRDN N/A
- Fundamental
- Price
- LTC $36.43
- VRDN $18.56
- Analyst Decision
- LTC Hold
- VRDN Strong Buy
- Analyst Count
- LTC 5
- VRDN 11
- Target Price
- LTC $38.80
- VRDN $38.80
- AVG Volume (30 Days)
- LTC 384.8K
- VRDN 857.8K
- Earning Date
- LTC 10-27-2025
- VRDN 08-06-2025
- Dividend Yield
- LTC 6.26%
- VRDN N/A
- EPS Growth
- LTC N/A
- VRDN N/A
- EPS
- LTC 1.81
- VRDN N/A
- Revenue
- LTC $213,197,000.00
- VRDN $305,000.00
- Revenue This Year
- LTC N/A
- VRDN N/A
- Revenue Next Year
- LTC $30.08
- VRDN $35,092.81
- P/E Ratio
- LTC $20.15
- VRDN N/A
- Revenue Growth
- LTC 8.74
- VRDN 5.90
- 52 Week Low
- LTC $31.70
- VRDN $9.90
- 52 Week High
- LTC $39.89
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- LTC 59.84
- VRDN 57.66
- Support Level
- LTC $35.81
- VRDN $18.22
- Resistance Level
- LTC $37.19
- VRDN $19.73
- Average True Range (ATR)
- LTC 0.54
- VRDN 0.99
- MACD
- LTC 0.07
- VRDN 0.02
- Stochastic Oscillator
- LTC 59.79
- VRDN 71.11
About LTC LTC Properties Inc.
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in seniors housing and healthcare facilities through mortgage loans, property lease transactions, and other investments. Its real estate investments includes different types of properties such as Independent living communities, Assisted living communities, Memory care communities, Skilled nursing centers and other types of properties.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).